In our study, we further investigated the efficacy of repurposed COVID-19 drugs to reduce mucin hyperexpression in SARS-CoV-2–infected epithelial cells, and in particular the mucins defining the signature associated with COVID-19 presentation and severity. The gene discussed is MUC5AC; the disease is COVID-19.